Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity

被引:607
作者
Smyth, MJ [1 ]
Dunn, GP
Schreiber, RD
机构
[1] Peter MacCallum Canc Ctr, Canc Immunol Program, E Melbourn, Vic 3002, Australia
[2] Washington Univ, Ctr Immunol, Dept Pathol & Immunol, St Louis, MO 63130 USA
来源
ADVANCES IN IMMUNOLOGY, VOL 90: CANCER IMMUNOTHERAPY | 2006年 / 90卷
关键词
D O I
10.1016/S0065-2776(06)90001-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cellular transformation and tumor development result from an accumulation Of mutational and epigenetic changes that alter normal cell growth and survival pathways. For the last 100 years, there has been a vigorous debate (is to whether the unmanipulated immune system can detect and eliminate such altered host derived cells despite the fact that cancer cells frequently express either abnormal proteins or abnormal levels of normal cellular proteins that function as tumor antigens. In this review, toe discuss the current state of this argument and point out some of the recent key experiments demonstrating that immunity not only protects the host from cancer development (i.e., provides a cancer immunosurveillance but also can promote tumor growth, sometimes by generating more aggressive tumors. The terminology "cancer immunoediting" has been used to describe this dual host protective and tumor promoting action Of immunity, and herein we summarize the ever-increasing experimental and clinical data that support the validity of this concept.
引用
收藏
页码:1 / 50
页数:50
相关论文
共 279 条
  • [11] Baxevanis CN, 2000, EUR J IMMUNOL, V30, P1957, DOI 10.1002/1521-4141(200007)30:7<1957::AID-IMMU1957>3.0.CO
  • [12] 2-7
  • [13] Interferon-alpha in tumor immunity and immunotherapy
    Belardelli, F
    Ferrantini, M
    Proietti, E
    Kirkwood, JM
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) : 119 - 134
  • [14] A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha
    Blasius, A
    Vermi, W
    Krug, A
    Facchetti, F
    Cella, M
    Colonna, M
    [J]. BLOOD, 2004, 103 (11) : 4201 - 4206
  • [15] Human tumor antigens recognized by T lymphocytes
    Boon, T
    vanderBruggen, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 725 - 729
  • [16] Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
    Borg, C
    Terme, M
    Taïeb, J
    Ménard, C
    Flament, C
    Robert, C
    Maruyama, K
    Wakasugi, H
    Angevin, E
    Thielemans, K
    Le Cesne, A
    Chung-Scott, V
    Lazar, V
    Tchou, I
    Crépineau, F
    Lemoine, F
    Bernard, J
    Fletcher, JA
    Turhan, A
    Blay, JY
    Spatz, A
    Emile, JF
    Heinrich, MC
    Mécheri, S
    Tursz, T
    Zitvogel, L
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) : 379 - 388
  • [17] Aids-related malignancies
    Boshoff, C
    Weiss, R
    [J]. NATURE REVIEWS CANCER, 2002, 2 (05) : 373 - 382
  • [18] Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma
    Bromberg, JF
    Horvath, CM
    Wen, ZL
    Schreiber, RD
    Darnell, JE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) : 7673 - 7678
  • [19] Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells
    Bronte, V
    Apolloni, E
    Cabrelle, A
    Ronca, R
    Serafini, P
    Zamboni, P
    Restifo, NP
    Zanovello, P
    [J]. BLOOD, 2000, 96 (12) : 3838 - 3846
  • [20] Burnet F M, 1971, Transplant Rev, V7, P3